Pacira BioSciences Reports First Quarter 2025 Financial Results
Pacira BioSciences Inc PCRX
News
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
Pacira BioSciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 14, 2025 Deadline to file Lead Plaintiff Motion
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRX
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
United States